The burgeoning field of obesity management has witnessed remarkable advancements with the emergence of dual GLP-3 receptor agonists, notably Retatrutide and Trizepatide. These novel therapies represent a significant https://carlyaooj184672.wikipowell.com/6753056/glp_3_receptor_agonists_retatrutide_trizepatide